Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. (not Madrigal Pharmaceuticals, Inc., as indicated in the metadata) on June 2, 2016. The report details a corporate governance event regarding the listing status of the company's common stock on The NASDAQ Stock Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock listing requirements.
Material Changes
- Listing Transfer: The company received approval to transfer its common stock listing from The Nasdaq Global Market to The Nasdaq Capital Market, effective June 3, 2016.
- Compliance Status: The transfer was necessitated by the company's failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days, a non-compliance issue notified on December 3, 2015.
- Trading Symbol: The company will continue to trade under the symbol "SNTA".
Outlook, Risks, and Contingencies
As a result of the transfer to The Nasdaq Capital Market and the satisfaction of specific listing criteria, the company was granted an additional 180-day period to regain compliance with the $1.00 minimum bid price requirement. This new compliance period extends through November 28, 2016. Failure to meet this requirement by the deadline could result in further delisting proceedings.
Investor Verification Checklist
- Verify the current trading status and symbol (SNTA) on The Nasdaq Capital Market.
- Monitor the company's stock price to ensure it meets the $1.00 minimum bid price requirement before the November 28, 2016 deadline.
- Review subsequent filings for any updates on the company's efforts to regain full compliance with Nasdaq listing standards.